CERS Logo

Cerus Corporation (CERS) 

NASDAQ
Market Cap
$326.86M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
320 of 968
Rank in Industry
39 of 120

Largest Insider Buys in Sector

CERS Stock Price History Chart

CERS Stock Performance

About Cerus Corporation

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Insider Activity of Cerus Corporation

Over the last 12 months, insiders at Cerus Corporation have bought $67,242 and sold $1.03M worth of Cerus Corporation stock.

On average, over the past 5 years, insiders at Cerus Corporation have bought $215,060 and sold $3.59M worth of stock each year.

Highest buying activity among insiders over the last 12 months: BJERKHOLT ERIC (director) — $48,600. Witney Frank (director) — $37,800. Swisher Daniel N JR (director) — $14,066.

The last purchase of 2,500 shares for transaction amount of $4,975 was made by Shan Hua (director) on 2024‑05‑13.

List of Insider Buy and Sell Transactions, Cerus Corporation

2024-09-04SaleChief Financial Officer
54,272
0.0299%
$2.15$116,826-15.64%
2024-09-03SaleChief Financial Officer
28,385
0.0153%
$2.18$61,919-18.49%
2024-08-15SaleChief Legal Officer
16,667
0.0092%
$2.06$34,4170.00%
2024-08-02SaleChief Medical Officer
21,605
0.0125%
$2.50$54,013-22.13%
2024-05-13Purchasedirector
2,500
0.0013%
$1.99$4,975-8.00%
2024-05-10Purchasedirector
2,000
0.0011%
$1.79$3,578+6.65%
2024-05-09Purchasedirector
20,000
0.0107%
$1.89$37,800-4.17%
2024-05-09Purchasedirector
2,500
0.0013%
$1.88$4,689-4.17%
2024-03-14SalePresident and CEO
63,611
0.0349%
$2.02$128,195-8.54%
2024-03-14SaleChief Scientific Officer
14,360
0.0077%
$1.97$28,352-8.54%
2024-03-14SaleChief Operating Officer
26,794
0.0144%
$1.97$52,902-8.54%
2024-03-14SaleChief Financial Officer
21,497
0.0116%
$1.97$42,444-8.54%
2024-03-14SaleChief Legal Officer
17,824
0.0096%
$1.97$35,192-8.54%
2024-03-14SaleChief Medical Officer
17,738
0.0095%
$1.97$35,022-8.54%
2024-03-13SalePresident and CEO
62,315
0.0349%
$2.06$128,182-9.90%
2024-03-13SaleChief Scientific Officer
14,067
0.0079%
$2.06$28,936-9.90%
2024-03-13SaleChief Operating Officer
26,247
0.0147%
$2.06$53,990-9.90%
2024-03-13SaleChief Financial Officer
21,058
0.0116%
$2.02$42,438-9.90%
2024-03-13SaleChief Legal Officer
17,460
0.0098%
$2.06$35,915-9.90%
2024-03-13SaleSVP Reg. & Quality
20,619
0.0113%
$2.02$41,553-9.90%

Insider Historical Profitability

23.06%
Greenman William MarinerPresident and CEO
3181281
1.713%
$1.76512+31.07%
CORASH LAURENCE MChief Scientific Officer
2339740
1.2599%
$1.76378+15.14%
Jayaraman Vivek KChief Operating Officer
878653
0.4731%
$1.7609
Green Kevin DennisChief Financial Officer
536093
0.2887%
$1.76030
Moore CarolSVP Reg. & Quality
490623
0.2642%
$1.76019
Jensen ChrystalChief Legal Officer
474245
0.2554%
$1.76020
Benjamin Richard JChief Medical Officer
438007
0.2358%
$1.76021
Witney Frankdirector
180059
0.097%
$1.7620+47.63%
BJERKHOLT ERICdirector
142133
0.0765%
$1.7640+22.01%
NACHTSHEIM JAMI Kdirector
108362
0.0583%
$1.7620+47.63%
Swisher Daniel N JRdirector
107045
0.0576%
$1.7635+22.26%
Shan Huadirector
32386
0.0174%
$1.7610
BAXTER INTERNATIONAL INC & SUBSIDIARIES PENSION TRUST10 percent owner
2192700
1.1807%
$1.7609
CASSIN BJdirector
487921
0.2627%
$1.7611+54.29%
ANDERSON TIMOTHY Bdirector
200765
0.1081%
$1.7616+47.63%
GLASSELL CLAESExecutive Officer and Director
176902
0.0953%
$1.7640+52.37%
SCHULZE GAILdirector
83420
0.0449%
$1.7614<0.0001%
Lucena Anndirector
72284
0.0389%
$1.7610
DAWSON WILLIAM JChief Financial Officer
53195
0.0286%
$1.7620+50.47%
MOORE TIMOTHY L.director
7911
0.0043%
$1.7620+33.47%
COZADD BRUCE Cdirector
5455
0.0029%
$1.7603

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
ARK Investment Management LLC$40.72M11.6521.55M+3.02%+$1.19M0.14
Baker Bros Advisors LP$36.81M10.5419.48M0%+$00.26
BlackRock$25.77M7.3813.64M-0.67%-$172,825.38<0.01
The Vanguard Group$18.87M5.49.98M+1.15%+$214,121.88<0.0001
PRIMECAP Management Co$16.22M4.648.58M-0.34%-$54,810.000.01
Sumitomo Mitsui Trust Holdings$14.65M4.197.75M+2.41%+$345,168.810.01
Nikko Asset Management Americas Inc$14.57M4.197.75M+2.41%+$343,342.520.11
Senvest Management Llc$13.85M3.967.33M+11.29%+$1.41M0.06
Wasatch Advisors$11.88M3.46.28M-3.77%-$464,779.370.06
Geode Capital Management$7.87M2.254.16M+3.73%+$282,826.39<0.01
State Street$6.94M1.993.67M+4.46%+$296,567.46<0.0001
D. E. Shaw & Co.$6.23M1.783.29M+14.88%+$806,421.390.01
Silvercrest Asset Management Group Inc$5.1M1.462.7M+4.44%+$216,646.900.04
IEQ Capital$4.05M1.162.14MNew+$4.05M0.06
Bank of America$3.98M1.142.11M+2,576.91%+$3.83M<0.0001
Voya Investment Management LLC$3.82M1.092.02M-22.05%-$1.08M<0.01
Morgan Stanley$3.8M1.092.01M+43.71%+$1.16M<0.0001
Charles Schwab$3.23M0.921.71M+3.01%+$94,190.04<0.01
Northern Trust$3.06M0.881.62M-1.04%-$32,086.53<0.0001
Silverarc Capital Management Llc$2.77M0.791.47M-2.27%-$64,462.230.03
Barclays$2.69M0.771.42M-10.54%-$316,456.36<0.01
Sepio Capital$2.55M0.731.35M+813.56%+$2.27M0.26
Citadel Advisors LLC$2.25M0.641.19M-53.3%-$2.56M<0.01
Assenagon Asset Management S.A.$2.09M0.61.11M+105.28%+$1.07M0.01
Goldman Sachs$1.7M0.49899,059+27.71%+$368,693.75<0.0001
Gsa Capital Partners Llp$1.62M0.46856,511-14.68%-$278,504.120.13
Millennium Management LLC$1.23M0.35648,670-75.98%-$3.88M<0.01
BNY Mellon$1.05M0.3557,373-10.14%-$118,860.21<0.0001
Nuveen$840,368.000.24444,6390%+$0<0.0001
Fidelity Investments$784,647.000.23415,157+9.06%+$65,191.79<0.0001
UBS$659,625.000.19349,008-14.14%-$108,629.62<0.0001
Raymond James Associates$596,333.000.17315,520-12.9%-$88,357.53<0.0001
Hood River Capital Management LLC$566,422.000.16299,694New+$566,422.000.01
Bouvel Investment Partners LLC$510,015.000.15269,849+4.75%+$23,103.380.24
Renaissance Technologies$509,000.000.15269,300-1.75%-$9,072.41<0.01
Engineers Gate Manager Lp$499,089.000.14264,068-1.71%-$8,682.670.01
Formula Growth Ltd$457,928.000.13242,2900%+$00.15
RhumbLine Advisers$456,809.000.13241,705+3.36%+$14,839.84<0.0001
Stifel$446,382.000.13236,177+2.03%+$8,892.60<0.01
Levin Easterly Partners Llc$405,001.000.12214,286New+$405,001.000.03
Marshall Wace$382,872.000.11202,578New+$382,872.00<0.0001
Man Group Plc$377,104.000.11199,526-41.82%-$271,016.45<0.01
T. Rowe Price$365,000.000.1192,873+4.88%+$16,997.87<0.0001
AllianceBernstein$331,701.000.1175,503-13.15%-$50,219.24<0.0001
Ameriprise Financial$331,225.000.1175,251+474.71%+$273,591.23<0.0001
Jane Street Capital$309,398.000.09163,703-67.4%-$639,621.86<0.0001
Walleye Capital$290,716.000.08153,818+551.85%+$246,117.67<0.01
HSBC$256,224.000.07135,568+41.14%+$74,685.38<0.0001
Stephens Inc.$219,531.000.06116,154-28.22%-$86,325.73<0.01
Cubist Systematic Strategies$211,946.000.06112,141+90.5%+$100,687.63<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.